IBM's Watson Health, Illumina team up on genomics sequencing, cancer research ZDNet

IBM said its Watson Health unit has partnered with Illumina, a company that offers genome data sequencing tools, to integrate and standardize interpretation for cancer research. Under the partnership, Watson Genomics will be integrated into Illumina's BaseSpace and Tumor Sequencing Process. Specifically, Watson Genomics will be available to interpret data produced by Illumina's TruSight Tumor 170, which is a solid tumor profiling panel. The system aims to detect variants across 170 genes and looks at both RNA and DNA. Previously: Playing House: How IBM's Watson is helping doctors diagnose the most rare and elusive illnesses AI, MD: How artificial intelligence is changing the way illness is diagnosed and treated The integration covers research not diagnostic procedures.